Background. This study evaluated the persistence of hepatitis B e antigen (HBeAg) seroconversion (which is considered to be an important therapeutic end point) after adefovir dipivoxil treatment.
lifetime. An estimated 500,000-1,200,000 people per year die of HBV-related diseases [1] [2] [3] .
The goal of treatment of chronic hepatitis B is to prevent progression of liver disease to cirrhosis, hepatic failure, or hepatocellular carcinoma. Loss of hepatitis B surface antigen and seroconversion to antibody to hepatitis B surface antigen, indicating resolution of hepatitis B, is the most desired end point but rarely occurs with current therapies [4] . Loss of hepatitis B e antigen (HBeAg) and seroconversion to antibody to HBeAg (anti-HBe; i.e., HBeAg seroconversion) may reduce the risk of disease progression and are commonly considered to be favorable outcomes of therapy; however, in some patients, HBeAg seroconversion ultimately evolves into the selection of precore mutants [2] .
Treatment with IFN results in HBeAg seroconversion in approximately one-third of patients chronically infected with HBV but is associated with a number of adverse effects that limit its tolerability. Follow-up studies involving patients who experienced HBeAg seroconversion during IFN or pegylated IFN-a-2a therapy revealed that HBeAg seroconversion was durable in 80%-90% of patients [5] [6] [7] [8] [9] [10] .
Viral suppression with lamivudine, an L-nucleoside analog, has been associated with improvements in liver histologic findings and HBeAg seroconversion and has an excellent safety profile. HBeAg seroconversion is observed in 16%-18% of patients after 1 year of lamivudine therapy. HBeAg seroconversion rates increased to 50% after 5 years of treatment [11] [12] [13] [14] [15] . Among the patients who experienced HBeAg seroconversion during lamivudine treatment, the durability of response after cessation of therapy has ranged from 50% to 77% [16] [17] [18] [19] [20] [21] . The efficacy of lamivudine is limited by the emergence of drugresistant HBV mutants. The proportion of patients with drug resistant virus increased from 23% after 1 year of treatment to 65% after 5 years of treatment [22] .
Entecavir, a nucleoside analog of guanosine, is a potent inhibitor of viral replication. HBeAg seroconversion occurred in 21% of patients after 1 year of treatment. Among the patients who achieved seroconversion at week 48, 82% had a sustained response 24 weeks after discontinuation of treatment [23] .
Adefovir dipivoxil, a nucleotide analog of adenosine monophosphate, has potent activity against wild-type and lamivudine-resistant HBV. HBeAg seroconversion was observed in 12% of patients after 1 year of treatment. A progressive increase in the frequency of HBeAg seroconversion has been documented over 240 weeks of adefovir treatment [24, 25] . The objective of this study was to investigate the durability of HBeAg seroconversion after discontinuation of therapy in patients who had experienced HBeAg seroconversion in a previous study of adefovir dipivoxil therapy (10 mg per day).
PATIENTS AND METHODS
Patients and study design. This was a long-term, observational study of the durability of HBeAg seroconversion in patients who had experienced confirmed HBeAg seroconversion (loss of HBeAg and appearance of anti-HBe at 2 consecutive visits that were at least 4 weeks apart) while receiving adefovir dipivoxil therapy (10 mg per day) in a prior study (study 437) [24, 25] . All patients tested HBeAg positive when they began the prior study (study 437). Patients who were HBeAg negative and anti-HBe positive and had a serum HBV DNA level !105 copies/mL at the 2 study visits before the final visit of the prior study were eligible. Patients were excluded if they received concomitant systemic drugs with possible activity against HBV, such as lamivudine, ganciclovir, lobucavir, famciclovir, entecavir, diaminopurine dioxolane, emtricitabine, clevudine, telbivudine, IFN, or thymosin-a. The study was conducted in accordance with the Declaration of Helsinki and was approved by local institutional review boards. All patients provided written informed consent.
Patients did not receive study drug in the present study. Visits were scheduled every 4 weeks for the first 16 weeks and every 24 weeks thereafter. Sustained HBeAg seroconversion was defined as a patient being HBeAg negative and anti-HBe positive at the last available measurement in the current study. Liver function tests (to determine total protein, albumin, aspartate aminotransferase, alanine aminotransferase [ALT], g-glutamyltransferase, alkaline phosphatase, and total bilirubin levels) were performed every 24 weeks. Study participants who enrolled within 16 weeks after discontinuation of adefovir dipivoxil therapy received visits every 4 weeks, with a chemistry panel performed for the first 16 weeks, to monitor for posttreatment hepatitis flares. Serial ultrasonography and a-fetoprotein monitoring were not performed as part of this study.
The duration of adefovir dipivoxil treatment before HBeAg seroconversion was defined as the duration of adefovir dipivoxil treatment before confirmed HBeAg seroconversion in the prior trial. The duration of adefovir dipivoxil treatment after HBeAg seroconversion was defined as the duration of adefovir dipivoxil treatment after confirmed HBeAg seroconversion in the prior trial. The duration of follow-up was defined as the period from discontinuation of use of adefovir dipivoxil in the prior trial to the last visit in the present study (i.e., the sum of the period from discontinuation of adefovir dipivoxil therapy in the prior trial to enrollment in the present study and the period from enrollment to the last visit in the present study).
HBV reactivation was defined as (1) a serum HBV DNA level of at least 10 5 copies/mL and a serum ALT concentration 12 times the upper limit of normal and/or (2) reappearance of HBeAg that had previously been cleared and absence of antiHBe. These criteria were to be confirmed at 2 consecutive visits at least 3 months apart. If HBV reactivation was confirmed by 1 or both of the criteria, patients were to return for a final study evaluation and permanently discontinue participation in the study. Serologic and virologic measurements. Serum HBeAg and anti-HBe levels were measured with use of commercially available assays (ETI-EBK-PLUS and ETI-AB-EBK-PLUS assays, respectively; DiaSorin). Serum HBV DNA levels were measured with use of a PCR assay (Roche Amplicor Monitor; Roche) and a PCR HBV DNA assay (Roche TaqMan; Roche). The lower limits of quantification for the PCR assay and the PCR HBV DNA assay were 1000 copies/mL and 169 copies/mL, respectively. Values from the PCR assay and the PCR HBV DNA assay that were !1000 copies/mL were set to 999 copies/mL for calculating summary statistics.
Genotypic analyses were performed with use of dideoxy sequencing (sensitivity, 25%) to identify changes within the precore and/or core promoter region of the HBV genome in viral isolates from patients with detectable viral replication (HBV DNA level, 11000 copies/mL). A nucleotide fragment (∼300 base pairs) encoding the precore or core promoter region of the HBV genome was sequenced and aligned to a known wildtype sequence. Changes within the core promoter region (positions 1762 and 1764) and the precore region (position 1896) were noted.
Statistical analysis. The distributions of categorical variables were compared by the x 2 test and Fisher's exact test.
Continuous variables were compared by the Wilcoxon ranksum test. Results were considered to be statistically significant at . P ! .05
RESULTS
During the previous study, 82 patients met the criteria for confirmed HBeAg seroconversion. Forty-five patients who had previously experienced seroconversion while receiving adefovir dipivoxil (10 mg per day) were enrolled in the present study; the other 37 patients did not choose to participate in the present study, and no additional follow-up information was available after discontinued participation in the previous study.
With regard to the baseline characteristics at the time of the last dose of adefovir dipivoxil, the median age of the patients was 35 years (range, 21-63 years), 64% were male, 73% were Asian, 27% were white, the median ALT level was 25 IU/L (range, 9-110 IU/L), and the median serum HBV DNA level was 3.0 log copies/mL (range, 3.0-3.2 copies/mL) (table 1). The median follow-up time from the end of treatment in the prior study to the last visit in the current study was 150 weeks (range, 13-252 weeks).
Forty-one patients maintained sustained HBeAg seroconversion at the last 2 assessments, and 4 patients did not maintain seroconversion at weeks 12 (3 patients) and 16 (1 patient) of follow-up. Of the 41 patients who experienced sustained HBeAg seroconversion, 21 (51%) had an HBV DNA level !1000 copies/ mL and 32 (78%) had a normal ALT level at the last available follow-up measurement. Thirty-eight (84%) of patients had received follow-up for the minimum of 1 year after their last dose of adefovir dipivoxil; 18 (40%) had received follow-up for 2-3 years, and 15 (33%) had received follow-up for 13 years. The reasons for discontinuation from the study were loss to follow-up (6 patients), protocol-defined HBV reactivation (6), investigator's request because of increases in serum HBV DNA level (2), death from metastatic hepatocellular carcinoma (1), concomitant medication prohibited by protocol (1), patient noncompliance (1), pregnancy (1), and change of residence to another state (1) .
The median duration of adefovir dipivoxil treatment was shorter before seroconversion (48 vs. 108 weeks;
) and P p .03 longer after seroconversion (41 vs. 22 weeks;
) for pa-P p .02 tients who experienced sustained HBeAg seroconversion, compared with the 4 patients who experienced seroreversion. No statistically significant difference was found with regard to age, sex, ethnicity, ALT level, serum HBV DNA level, and viral genotype between patients who did and did not experience sustained seroconversion (table 2) .
Testing for the presence of precore and/or core promoter mutations was attempted for all patients with an HBV DNA level 11000 copies/mL at the last study visit. However, only 13 of the 20 patients with an HBV DNA level 11000 copies/mL had stored serum samples available for testing to determine whether precore (change from G to A at nucleotide 1896) and/ or core promoter (change from A to T at nucleotide 1764 and change from G to A at nucleotide 1764) mutations were present. Of 7 patients with an HBV DNA level 11000 copies/mL, 6 did not have a stored sample available for testing and 1 patient had a sample that could not be amplified. Core promoter mutations and/or precore mutations were observed in 11 (85%) of the 13 clinical isolates evaluated, and single nucleotide insertions were found in 2 of the 13 clinical isolates (table 3) . Four patients were shown to harbor virus with the precore mutation (1 with G1896G/A and 3 with G1896A), 1 patient harbored a single core promoter mutation (A1762A/T), 5 patients harbored both the A1762T and G1764A mutations, and 1 patient harbored both precore (G1896G/A) and core promoter (G1764G/A) mu- tations. Genotypic analysis of serum samples before adefovir dipivoxil therapy was also performed for these 13 patients. Notably, 8 of the 11 patents with basal core promoter and/or precore mutations at the last visit had these mutations before initiation of adefovir dipivoxil therapy (table 4) .
DISCUSSION
HBeAg seroconversion has generally been considered to be a favorable indicator of response in the treatment of chronic hepatitis B infection. In this study, HBeAg seroconversion at the last dose of adefovir dipivoxil was sustained in 41 patients over a median follow-up period while not receiving treatment of 150 weeks. Four patients experienced seroreversion within 16 weeks after discontinuation of adefovir dipivoxil therapy. The only differences between patients who did and did not experience sustained HBeAg seroconversion were the median durations of adefovir dipivoxil treatment before and after seroconversion; the duration was shorter before seroconversion and longer after seroconversion for patients who experienced sustained seroconversion, compared with 4 patients who experienced seroreversion. Previous studies assessing the durability of lamivudine-induced HBeAg seroconversion have suggested that longer treatment after seroconversion increased sustained response. Song et al. [21] reported that 14 months of additional lamivudine therapy significantly decreased the seroreversion rate. Another lamivudine trial conducted by Lee et al. [20] revealed that twothirds of the patients who experienced seroreversion had received !10 months of additional therapy. In a study of determinants for sustained HBeAg seroconversion, at least 8 months of additional lamivudine treatment was required to ensure a significantly higher sustained response [16] . This finding had also been noted by other authors and prompted management guidelines to recommend continuing oral therapy for at least 6 months after confirmed HBeAg seroconversion to reduce posttreatment seroreversion [2] . The results of the present study support the continuation of adefovir dipivoxil therapy for a longer time after confirmed HBeAg seroconversion and, in view of the precore and/or core promoter mutation findings, possibly 11 year. Because hepatitis B surface antigen loss is generally prefaced by HBeAg seroconversion, the subset of patients who experience seroconversion may represent those most likely to clear hepatitis B surface antigen while continuing to receive treatment.
Of the patients who experienced sustained HBeAg seroconversion, approximately one-half had an HBV DNA level !1000 copies/mL at last the follow-up visit when they were not receiving treatment. However, among the remaining patients with active viremia, basal core promoter and/or precore mutations were present in 11 of the 13 patients with available samples for testing, which demonstrates that these patients had experienced progression to HBeAg-negative disease despite experiencing sustained HBeAg seroconversion. Interestingly, 8 of the 11 patents with basal core promoter and/or precore mutations at the last visit also had these mutations before initiation of adefovir dipivoxil therapy. Of note, 6 of these 11 patients had an HBV DNA level !10 4 copies/mL (range, 1046-3079 copies/mL), and 5 were viremic (HBV DNA level, 110 4 copies/mL); thus, more than one-half harbored precore and/or core promoter mutations but did not have high-level viremia, and even low levels of replication can potentially lead to escape mutations and, probably, disease progression. Recent studies [26, 27] have revealed that presence of serum HBV DNA was a risk factor for cirrhosis and hepatocellular carcinoma, even if the patients had low serum HBV DNA levels. In addition, the risk of accumulating accessory mutations may exist. The relatively small sample of patients and the number of patients lost to followup are limitations of this study. These data show that HBeAg seroconversion might be an inadequate therapeutic end point for stopping therapy. The patients who have experienced HBeAg seroconversion and have viremia may consider continued antiviral treatment or adding a more potent drug that is not cross-resistant-a suggestion that is derived from the report by Keeffe et al. [28] .
Some guidelines for the treatment of HBeAg-positive chronic hepatitis B recommend that nucleoside analog treatment should be continued until the patient has achieved HBeAg seroconversion and completed at least 6 months of additional treatment after the appearance of anti-HBe (with a serum HBV DNA level !105 copies/mL [29] or without mention of serum HBV DNA levels [2] ). The present study revealed that, despite experiencing sustained HBeAg seroconversion after discontinuation of antiviral therapy, most of the patients with viremia developed precore and/or basal core promoter mutants, even at a low viral titer. Therefore, HBeAg seroconversion alone may not be an adequate treatment end point. Regular HBV DNA monitoring may be needed for patients who discontinue antiviral treatment when HBeAg seroconversion is confirmed.
The possible influence of viral genotype on durability of HBeAg seroconversion has also been studied. Chien et al. [16] found that viral genotype C was associated with a higher relapse rate than viral genotype B in patients receiving lamivudine therapy. In the present study, all 4 patients who experienced seroreversion were infected with viral genotype C. However, because viral genotype C was the most predominant viral genotype in this group of patients who experienced seroconversion, no statistically significant association was found between HBV viral genotype and loss of seroconversion.
In conclusion, most patients experienced sustained HBeAg seroconversion after discontinuation of adefovir dipivoxil therapy for a median of 3 years. Prolonged antiviral therapy after HBeAg seroconversion appeared to increase the likelihood of sustained HBeAg seroconversion, and a longer duration of antiviral therapy might be needed in patients who experience seroconversion late after initiation of therapy. However, onehalf of the patients who experienced sustained HBeAg seroconversion had viremia, and most of them had precore and/ or basal core promoter mutants, which usually existed before initiation of adefovir dipivoxil therapy. The clinical outcome of these patients needs to be illustrated in the future.
